Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide for osteoporosis after alendronate
NCT00191893Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label trial of teriparatide in osteoporosis (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Conventional histomorphometric parameters (bone turnover, bone formation rate, and bone volume) and microdamage accumulation from iliac crest biopsies. Started Sep 2003; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00191893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191893.